Boston Scientific Corporation has announced its agreement to acquire Cortex, a medical technology company specializing in diagnostic mapping solutions for atrial fibrillation (AF). Cortex’s innovative OptiMap System uses a basket catheter and proprietary algorithm to pinpoint AF triggers outside the pulmonary veins, enabling physicians to create precise, individualized ablation strategies. With FDA 510(k) clearance in 2023 and promising results from the FLOW-AF clinical trial showing a 51% improvement in AF-free outcomes over traditional methods, the OptiMap System represents a transformative approach to addressing complex AF cases.
Boston Scientific, a global leader in medical technologies for over 45 years, aims to integrate Cortex’s advanced technology into its electrophysiology portfolio. Cortex CEO Duke Rohlen emphasized that this partnership will expand access to more precise AF treatment worldwide. Boston Scientific plans to finalize the acquisition in the first half of 2025, with ongoing clinical trials, such as the 300-patient RESOLVE-AF study, to further validate the OptiMap System's effectiveness.
